Literature DB >> 17707916

Modulation of human lung fibroblast functions by ciclesonide: evidence for its conversion into the active metabolite desisobutyryl-ciclesonide.

Silvia Boero1, Federica Sabatini, Michela Silvestri, Loredana Petecchia, Antonio Nachira, Annalisa Pezzolo, Lucia Scarso, Giovanni A Rossi.   

Abstract

BACKGROUND: Ciclesonide, an inhaled corticosteroid administered as inactive compound with almost no binding affinity for the glucocorticoid receptor, is clinically effective in asthma being converted by airway epithelial cells into its active metabolite desisobutyryl-(des)-ciclesonide. AIM: To evaluate whether ciclesonide could directly modulate in vitro bronchial fibroblast functions being converted into des-ciclesonide by these pluripotent cells involved in the regulation of airway inflammation and remodelling.
METHODS: Ciclesonide (0.09-9.0 microM) was added to a human adult lung fibroblast cell line (CCL-202), seeded in medium in the presence of the following cytokines and growth factors: (a) basic fibroblast growth factor (bFGF) for cell proliferation, measured by tritiated thymidine ([3H]TdR) incorporation; (b) tumour necrosis factor (TNF)-alpha, to stimulate intercellular adhesion molecule (ICAM)-1 expression and monocyte chemoattractant protein-1 (MCP-1) and eotaxin release, evaluated by flow cytometry and ELISA, respectively; (c) transforming growth factor (TGF)-beta1, for induction of alpha smooth muscle actin (alpha-SMA) protein expression and modification of the organization of alpha-SMA stress fibres, evaluated by Western blot analysis and fluorescence microscopy.
RESULTS: The presence of ciclesonide in cell cultures induced a significant downregulation of: (a) bFGF-induced fibroblast proliferation and TNF-alpha-induced ICAM-1 expression, at the 0.3-9.0 microM concentrations (p<0.05); (b) TNF-alpha-induced MCP-1 release, at all the concentrations tested (p<0.05); (c) TNF-alpha-induced eotaxin release, at the three highest concentrations (0.9-9.0 microM) (p<0.05); (d) TGF-beta1-induced of alpha-SMA protein expression at the 0.3-3.0 microM concentrations, associated with a reduction in the organization of alpha-SMA stress fibres.
CONCLUSIONS: These data show at cellular level an effective anti-inflammatory activity of ciclesonide on human lung fibroblasts and support the hypothesis that also these cells, in addition to airway epithelial cells, may be involved in converting the parental compound into its active metabolite in the airways.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707916     DOI: 10.1016/j.imlet.2007.06.010

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  4 in total

Review 1.  Ciclesonide: a review of its use in the management of asthma.

Authors:  Emma D Deeks; Caroline M Perry
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  Profile of ciclesonide for the maintenance treatment of asthma.

Authors:  Effie Singas; Jill P Karpel
Journal:  Ther Clin Risk Manag       Date:  2011-08-19       Impact factor: 2.423

3.  Rhinovirus-induced basic fibroblast growth factor release mediates airway remodeling features.

Authors:  Chrysanthi L Skevaki; Stelios Psarras; Eleni Volonaki; Harris Pratsinis; Irini S Spyridaki; Mina Gaga; Vassiliki Georgiou; Stylianos Vittorakis; Aurica G Telcian; Paraskevi Maggina; Dimitris Kletsas; Dimitrios Gourgiotis; Sebastian L Johnston; Nikolaos G Papadopoulos
Journal:  Clin Transl Allergy       Date:  2012-08-21       Impact factor: 5.871

Review 4.  Fibroblast-to-myofibroblast transition in bronchial asthma.

Authors:  Marta Michalik; Katarzyna Wójcik-Pszczoła; Milena Paw; Dawid Wnuk; Paulina Koczurkiewicz; Marek Sanak; Elżbieta Pękala; Zbigniew Madeja
Journal:  Cell Mol Life Sci       Date:  2018-08-12       Impact factor: 9.261

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.